AU1977997A - Non-peptidyl vasopressin v1a antagonists - Google Patents

Non-peptidyl vasopressin v1a antagonists

Info

Publication number
AU1977997A
AU1977997A AU19779/97A AU1977997A AU1977997A AU 1977997 A AU1977997 A AU 1977997A AU 19779/97 A AU19779/97 A AU 19779/97A AU 1977997 A AU1977997 A AU 1977997A AU 1977997 A AU1977997 A AU 1977997A
Authority
AU
Australia
Prior art keywords
antagonists
vasopressin
peptidyl
peptidyl vasopressin
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19779/97A
Other languages
English (en)
Inventor
Robert F. Bruns
Robin D. G. Cooper
Bruce A Dressman
David C. Hunden
Stephen W Kaldor
Gary A. Koppel
John R. Rizzo
Jeffrey James Skelton
Mitchell I. Steinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605044.8A external-priority patent/GB9605044D0/en
Priority claimed from GBGB9605046.3A external-priority patent/GB9605046D0/en
Priority claimed from GBGB9605045.5A external-priority patent/GB9605045D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1977997A publication Critical patent/AU1977997A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AU19779/97A 1996-02-23 1997-02-20 Non-peptidyl vasopressin v1a antagonists Abandoned AU1977997A (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US012215 1993-10-04
US1214996P 1996-02-23 1996-02-23
US1221596P 1996-02-23 1996-02-23
US1218896P 1996-02-23 1996-02-23
US012149 1996-02-23
US012188 1996-02-23
GB9605046 1996-03-09
GB9605045 1996-03-09
GBGB9605044.8A GB9605044D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the vasopressin v1a receptor
GBGB9605046.3A GB9605046D0 (en) 1996-03-09 1996-03-09 Method for antagonism of the tachykinin receptor with non-peptide agents
GB9605044 1996-03-09
GBGB9605045.5A GB9605045D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the oxytocin receptor
PCT/US1997/003039 WO1997030707A1 (en) 1996-02-23 1997-02-20 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS

Publications (1)

Publication Number Publication Date
AU1977997A true AU1977997A (en) 1997-09-10

Family

ID=27547258

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19779/97A Abandoned AU1977997A (en) 1996-02-23 1997-02-20 Non-peptidyl vasopressin v1a antagonists

Country Status (10)

Country Link
US (3) US6204260B1 (enExample)
EP (1) EP0939632B1 (enExample)
JP (1) JP4212112B2 (enExample)
AT (1) ATE305781T1 (enExample)
AU (1) AU1977997A (enExample)
CA (1) CA2246753C (enExample)
DE (1) DE69734321T2 (enExample)
DK (1) DK0939632T3 (enExample)
ES (1) ES2248840T3 (enExample)
WO (1) WO1997030707A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
CN1382047A (zh) * 1999-08-16 2002-11-27 雷瓦尔克斯药品有限公司 神经病治疗组合物和方法
BR0015299A (pt) 1999-11-04 2003-04-15 Johnson & Johnson Benzotiazepinas substituìdas não-peptìdicas como antagonistas de vasopressina
DK1406893T3 (da) 2001-06-15 2007-08-06 Vicuron Pharm Inc Bicykliske pyrrolidinforbindelser
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
JP4494015B2 (ja) * 2001-10-12 2010-06-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド β−ラクタミル・バソプレッシンＶ１ａ拮抗剤
WO2003051314A2 (en) * 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004030635A2 (en) * 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
TW200526651A (en) * 2003-10-03 2005-08-16 Serenix Pharmaceuticals Llc 3-substituted β-lactamyl vasopressin V1a antagonists
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006102308A2 (en) * 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
US20060292203A1 (en) * 2005-06-08 2006-12-28 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
JP5328349B2 (ja) * 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
MX391408B (es) * 2005-11-01 2025-03-21 Impact Biomedicines Inc Inhibidores de biaril meta-pirimidina de cinasas.
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
CN102413814A (zh) * 2009-04-29 2012-04-11 瑞恩药品公司 用于神经保护和治疗神经变性病症的克拉维酸类物质制剂
JP2013535425A (ja) 2010-07-01 2013-09-12 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 心的外傷後ストレス障害を治療する方法
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP7255967B2 (ja) 2014-03-28 2023-04-11 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
CN111295373B (zh) * 2017-09-15 2024-12-10 阿泽凡药物公司 用于治疗脑损伤的组合物和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US4673737A (en) 1985-08-02 1987-06-16 Harvard University 7-acylamino-(or 7-amino)-3-trifluoromethylsulfonyloxy-1-carba(1-dethia)-3-cephem-4-carboxylic acids and esters thereof
EP0215435B1 (en) 1985-09-09 1993-03-03 Otsuka Pharmaceutical Co., Ltd. 2-oxa-isocephem compounds, compositions containing same and processes for preparing same
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) * 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
DK123488A (da) 1987-03-09 1988-09-10 Otsuka Pharma Co Ltd 2-oxa-isocephemforbindelser, praeparater indeholdende dem, og fremgangsmaader til fremstilling af dem
US5373089A (en) 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
US5068232A (en) 1990-04-10 1991-11-26 American Cyanamid Company Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them
US5521307A (en) * 1992-02-18 1996-05-28 Eli Lilly And Company Methods and compounds for the preparation of carbacephems
CA2147129A1 (en) * 1992-10-27 1994-05-11 James B. Doherty New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996016333A1 (en) * 1994-11-23 1996-05-30 Affymax Technologies, N.V. METHODS FOR SYNTHESIZING DIVERSE COLLECTIONS OF β-LACTAM COMPOUNDS
JPH11503728A (ja) * 1995-03-31 1999-03-30 シンファー ラボラトリーズ，インコーポレーティッド システイン・プロテイナーゼ阻害剤として有用な新規な４−置換−３−ペプチジル−アゼチジン−２−オン誘導体
AU5487496A (en) * 1995-05-03 1996-11-21 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs

Also Published As

Publication number Publication date
ATE305781T1 (de) 2005-10-15
DE69734321D1 (de) 2006-02-16
US6521611B2 (en) 2003-02-18
CA2246753C (en) 2005-05-10
EP0939632A4 (en) 2002-09-25
DK0939632T3 (da) 2006-01-30
DE69734321T2 (de) 2006-08-10
US20020049187A1 (en) 2002-04-25
EP0939632B1 (en) 2005-10-05
CA2246753A1 (en) 1997-08-28
JP2000504731A (ja) 2000-04-18
US6610680B1 (en) 2003-08-26
EP0939632A1 (en) 1999-09-08
WO1997030707A1 (en) 1997-08-28
JP4212112B2 (ja) 2009-01-21
ES2248840T3 (es) 2006-03-16
US6204260B1 (en) 2001-03-20

Similar Documents

Publication Publication Date Title
AU1977997A (en) Non-peptidyl vasopressin v1a antagonists
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU3766897A (en) Fused heterocyclic compounds as protein tyrosine kinase inhibitors
AU3642795A (en) Endothelin receptor antagonists for the treatment of emesis
AU6219398A (en) Use of central cannabinoid receptor antagonists for regulating appetence
AU4091696A (en) Estrogen agonists/antagonists
AU8030598A (en) Indole compounds as cox-2 inhibitors
AU7131196A (en) Pyrimidine derivatives as 5ht2c-receptor antagonists
AU3213795A (en) Endothelin antagonists
MY126476A (en) 2-methyl-thieno-benzodiazepine formulation
AU3808595A (en) Novel acid pyrazole and pyrazolone derivatives for use as endothelin receptor antagonists
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
WO2000033837A3 (en) Myt1 kinase inhibitors
AU7211996A (en) Pyridazinones as endothelin-receptor antagonists
AU8871898A (en) Phenylindole derivatives as 5-ht2a receptor antagonists
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists
AU2608199A (en) Laser reference line device capable of leveling automatically
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
AU3416995A (en) Endothelin receptor antagonists
AU3055397A (en) Heterocyclic compounds
AU4904800A (en) Identification of compounds for modulating dimeric receptors
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
AU5333796A (en) Phenyl derivatives useful as endothelin receptor antagonists
AU6455198A (en) Method for the identification of genetic subtypes
AU1691799A (en) 4-(3-indolyl)imidazole derivatives